Biomarker for Cystic Fibrosis

Overview

International, multicenter, observational, longitudinal study to identify biomarker/s for Cystic fibrosis and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s

Full Title of Study: “Biomarker for Cystic Fibrosis: An International, Multicenter, Observational, Longitudinal Protocol”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 31, 2022

Detailed Description

Cystic fibrosis (CyFi) is a progressive hereditary disease with the prevalence of 1 in 2500. CyFi is an autosomal recessive disease caused by pathogenic variant/s in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene encoding Cftr protein. CyFi causes chronic respiratory damage. Pulmonary findings occur already in infancy, which raises questions whether obstruction might be congenital. Thick, sticky mucus clogs the airways, reduces muco-ciliary clearance and leads to problems with breathing and recurrent bacterial (Pseudomonas aeruginosa) infections, which causes over time the formation of scar tissue (fibrosis) and cysts in the lungs.There is no cure for CyFi; however, symptomatic treatment can help relieve symptoms. The aim of this study is to identify biomarkers for Cystic fibrosis disease and to explore their clinical robustness, specificity, and long-term variability. An ideal biomarker plays an essential role in the early diagnosis, prediction and therapeutic monitoring of a specific disorder.

Arms, Groups and Cohorts

  • Participants genetically diagnosed with Cystic fibrosis
    • Participants diagnosed with Cystic fibrosis aged between 2 months and 50 years

Clinical Trial Outcome Measures

Primary Measures

  • Identification of Cystic fibrosis biomarker/s
    • Time Frame: 36 months
    • All samples will be analyzed for the identification of biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC

Secondary Measures

  • Exploring the clinical robustness, specificity, and long-term variability of Cystic fibrosis biomarker/s
    • Time Frame: 36 months
    • Samples will be analyzed for the identified biomarker candidates via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.

Participating in This Clinical Trial

Inclusion Criteria

  • Informed consent is obtained from the participant or the parent/ legal guardian – The participant is aged between 2 months and 50 years – The diagnosis of Cystic fibrosis is genetically confirmed by CENTOGENE EXCLUSION CRITERIA:

  • Informed consent is not obtained from the participant or from the parent/ legal guardian – The participant is younger than 2 months or older than 50 years – The diagnosis of Cystic fibrosis is not genetically confirmed by CENTOGENE

Gender Eligibility: All

Minimum Age: 2 Months

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • CENTOGENE GmbH Rostock
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Peter Bauer, Prof. Dr., Study Chair, Centogene GmbH

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.